Abstract
Over the years, proteases have been implicated in the development of tumors. The proteolytic network, which critically modulates the functioning of a normal cell, is often dysregulated in cancers. In the recent past, the identification of a subpopulation of cancer cells, termed as cancer stem cells (CSCs), has helped gain a better understanding of the complex mechanisms involved in cancer development, progression, as well as recurrence. In this context, it is of considerable importance to comprehend the pivotal role of proteases in regulating the fate of cancer cells via the CSCs. In fact, the proteolytic network influences cancer cell’s fate via CSC and its associated niche, which coordinates the functions of CSCs. In this chapter, we have emphasized on the dynamic role displayed by the proteases in regulating numerous steps of tumorigenesis commencing from tumor initiation, angiogenesis, invasion and metastasis. Apart from this, CSCs also execute a survival mechanism with the help of proteases, upon induction of apoptosis. We have also revisited the mechanisms underlying the contribution of proteases in tumor drug resistance, which ultimately leads to cancer relapse, and the role of CSCs in the same. Similarly, proteases are also intricately involved in inflammation and immune surveillance of CSCs. Given the important role of proteases in carcinogenesis, further development of antiprotease therapeutics may enable better treatment procedures and minimize the risk of recurrence. This chapter has, therefore, epitomized the complex crosstalk involving proteases, CSCs and its niche.
The authors Shruti Banerjee and Apoorva Bhattacharya have contributed equally towards this chapter.
References
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14(3):275–291
Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768
Kise K, Kinugasa-Katayama Y, Takakura N (2016) Tumor microenvironment for cancer stem cells. Adv Drug Deliv Rev 99:197–205
Pietras K, Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324–1331
Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337
Raza A, Franklin MJ, Dudek AZ (2010) Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85:593–598
Mao Y, Keller ET, Garfield DH et al (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32:303–315
Hewitt R, Danø K (1996) Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein 49:163–173
Mason SD, Joyce JA (2011) Proteolytic networks in cancer. Trends Cell Biol 21:228–237
Lopez-Otin C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J BiolChem 283:30433–30437
López-Otín C, Hunter T (2010) The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 10:278–292
Yang Y, Hao Hong H, Yin Zhang Y et al (2009) Molecular imaging of proteases in cancer. Cancer Growth Metastasis 2:13–27
Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2:613–618
Zucker S, Cao J, Chen WT (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642–6650
Lopez-Otin C, Overall CM (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3:509–519
Rakashanda S, Rana F, Rafiq S et al (2012) Role of proteases in cancer: a review. Biotechnol Mol Biol Rev 7:90–101
Quesada V, Ordóñez GR, Sánchez LM et al (2009) The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 37:D239–D243
Puente XS, Sánchez LM, Overall CM et al (2003) Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4:544–558
Choi KY, Swierczewska M, Lee S et al (2012) Protease-activated drug development. Theranostics 2:156–178
Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5:785–799
López-Otín C, Matrisian LM (2007) Emerging roles of proteases in tumor suppression. Nat Rev Cancer 7:800–808
Schroter F, Adjaye J (2014) The proteasome complex and the maintenance of pluripotency: sustain the fate by mopping up? Stem Cell Res Ther 5:24
Rape M, Jentsch S (2002) Taking a bite: proteasomal protein processing. Nature Cell Bio 4:E113–E116
Yasutaka O, Keiichi IN (2012) UPS delivers pluripotency. Cell Stem Cell 11:728–730
Pan J, Zhang Q, Wang Y et al (2010) 26S Proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS ONE 5:e13298
Chinchar E, Makey KL, Gu, JW (2014) Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 6
Hill RP, Marie-Egyptienne DT, Hedley DW (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19:106–111
Catalano V, Turdo A, Di Franco S et al (2013) Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 23:522–532
Han L, Shi S, Gong T et al (2013) Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharm Sin B 3:65–75
Clarke MF, Dick JE, Dirks PB (2006) Cancer stem cells—perspectives on current status and future directions: ACCR workshop on cancer stem cells. Cancer Res 66:9339–9344
Baker M (2008) Cancer stem cells, becoming common. Nat Rep Stem Cells. doi:10.1038/stemcells.2008.153
Seton-Rogers S (2011) Cancer stem cells. VEGF promotes stemness. Nat Rev Cancer 11:831
Tang S, Xiang T, Huang S et al (2016) Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling. Cancer Lett 376:137–147
Bussolati B, Grange C, Sapino A et al (2009) Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 13:309–319
Kumar D, Kumar S, Gorain M et al (2016) Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol pii: S0022-202X(16)32232-1
Saha S, Mukherjee S, Mazumdar M et al (2014) Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Transl Res 165:558–577
Saha S, Mukherjee S, Khan P et al (2016) Aspirin suppress the acquisition of chemoresistance in breast cancer by disrupting an NFкB-IL6 signaing axis responsible for the generation of Cancer Stem Cells. Cancer Res 76:2000–2012
Mukherjee S, Mazumdar M, Chakraborty S et al (2014) Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/β-catenin negative feedback loop. Stem Cell Res Ther 5:116
Mukherjee S, Manna A, Bhattacharjee P et al (2016) Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells. Oncogene. doi:10.1038/onc.2016.26
Tang DG (2012) Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22:457–472
Chakraborty C, Chin KY, Das S (2016) miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis. Tumor Biol. doi:10.1007/s13277-016-5156-1
Korkaya H, Liu S, Wicha MS (2006) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121:3804–3809
Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441:1075–1079
Fessler E, Dijkgraaf FE, De Sousa E, Melo F et al (2013) Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett 34:97–104
Bennewith KL, Durand RE (2004) Quantifying transient hypoxia in human tumorxenografts by flow cytometry. Cancer Res 64:6183–6189
Wong DJ, Liu H, Ridky TW et al (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2:333–344
Vermeulen L, De Sousa E, Melo F, van der Heijden M (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476
Ohishi K, Varnum-Finney B, Bernstein ID (2002) The Notch pathway: modulation of cell fate decisions in hematopoiesis. Int J Hematol 75:449–459
Chanmee T, Ontong P, Mochizuki N et al (2014) Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor β (TGF-β)-Snail signaling axis. J BiolChem 289:26038–26056
Kitamura T, Qian BZ, Pollard JW (2015) Immune cell promotion of metastasis. Nat Rev Immunol 15:73–86
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49–61
Siefert SA, Sarkar R (2012) Matrix metalloproteinases in vascular physiology and disease. Vascular 20:210–216
Kessenbrock K, Dijkgraaf GJ, Lawson DA et al (2013) A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell 13:300–313
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
Chen J (2012) Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res 114:1–20
Hagerling C, Casbon AJ, Werb Z (2015) Balancing the innate immune system in tumor development. Trends Cell Biol 25:214–220
Boumahdi S, Driessens G, Lapouge G (2014) SOX2 controls tumor initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511:246–250
Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells. Cell Stem Cell 16:225–238
Chen DY, Liu H, Takeda S et al (2010) Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res 70:5358–5367
Hsieh JJ, Cheng EH, Korsmeyer SJ (2003) Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115:293–303
Wünsch D, Hahlbrock A, Jung S et al (2016) Taspase1: a ‘misunderstood’ protease with translational cancer relevance. Oncogene 35:3351–3364
Kumar S, Kulkarni R, Sen S (2016) Cell motility and ECM proteolysis regulate tumor growth and tumor relapse by altering the fraction of cancer stem cells and their spatial scattering. PhysBiol 13:036001
Sevenich L, Joyce JA (2014) Pericellular proteolysis in cancer. Genes Dev 28:2331–2347
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Muthukkaruppan VR, Kubai L, Auerbach R (1982) Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst 69:699–708
Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balance proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153
Parangi S, O’Reilly M, Christofori G et al (1996) Angiogenesis therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002–2007
Dameron KM, Volpert OV, Tainsky MA et al (1994) Control of angiogenesis in fibroblasts by p53 regulation of thorombospondin-1. Science 265:1582–1584
Gu JW, Rizzo P, Pannuti A et al (2012) Notch signals in the endothelium and cancer “stem-like” cells: opportunities for cancer therapy. Vascular Cell 4:7
Matsuda S, Yan T, Mizutani A et al (2014) Cancer stem cells maintain a hierarchy of differentiation by creating their niche. Int J Cancer 135:27–36
Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447
Kiba A, Yabana N, Shibuya M (2003) A set of loop-1 and -3 structures in the novel VEGF family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling. J Biol Chem 278:13453–13461
Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848
Hadjimichael C, Chanoumidou K, Papadopoulou N (2015) Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells 7:1150–1184
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174
Yana I, Weiss SJ (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proproteinconvertases. Mol Biol Cell 11:2387–2401
Handsley MM, Edwards DR (2005) Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 115:849–860
Kajita M, Itoh Y, Chiba T et al (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153:893–904
Seiki M (2003) Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194:1–11
Brooks PC, Stromblad S, Sanders LC et al (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683–693
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097–1105
Brauer R, Beck IM, Roderfeld M et al (2011) Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen. BMC Biochem 12:38
Felbor U, Dreier L, Bryant RA et al (2000) Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19:1187–1194
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67
Li S, Huang NF, Hsu S (2005) Mechanotransduction in endothelial cell migration. J CellBiochem 96:1110–1126
Iivanainen E, Kähäri VM, Heino J et al (2003) Endothelial cell-matrix interactions. Microsc Res Tech 60:13–22
Du R, Lu KV, Petritsch C (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–220
Wojtukiewicz MZ, Sierko E, Klement P et al (2001) The hemostatic system and angiogenesis in malignancy. Neoplasia 3:371–384
Qiao L, Liang N, Zhang J et al (2015) Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med 19:315–326
Zijl FV, Krupitza G, Mikulits W (2011) Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 728:23–34
Iqbal W, Alkarim S, AlHejin A et al (2016) Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis. Oncotarget. doi:10.18632/oncotarget.10942
Chabottaux V, Ricaud S, Host L et al (2009) Membrane-type 4 matrix metalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumor vascular architecture. J Cell Mol Med 13:4002–4013
Klimstra D, Reinheckel T, Peters C et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20:543–556
Noë V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118
Najy AJ, Day KC, Day ML (2008) Theectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 283:18393–18401
Grabowska MM, Sandhu B, Day ML (2012) EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal 24:532–538
Juncker-Jensen A, Deryugina EI, Rimann I (2013) Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination. Cancer Res 73:4196–4211
Feng S, Cen J, Huang Y (2011) Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS ONE 6:e20599
Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27:2192–2206
Mani SA, Guo W, Liao MJ (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Nishida C, Kusubata K, Tashiro Y et al (2011) MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells. Blood 119:5405–5416
Wang Z, von Au A, Schnölzer M et al (2016) CD44v6-competent tumorexosomes promote motility, invasion and cancer-initiating cell marker expression. Oncotarget. doi:10.18632/oncotarget.10580
D’Eliseo D, Di Rocco G, Loria R et al (2016) Epitelial-to-mesenchimal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells. J ExpClin Cancer Res. doi:10.1186/s13046-016-0302-6
Gao Y, Feng J, Wu L et al (2015) Expression and pathological mechanism of MMP-9 and HIF-2α in CD133(+) lung cancer stem cells. Zhonghua Yi XueZaZhi 95:2607–2611
Talukdar S, Das SK, Pradhan AK, Emdad et al (2016) Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells. Oncotarget. doi:10.18632/oncotarget.10851
Ito K, Ito K (2016) Metabolism and the control of cell fate decisions and stem cell renewal. Annu Rev Cell Dev Biol. doi:10.1146/annurev-cellbio-111315-125134
Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14:329–341
Miyamoto S, Yano K, Sugimoto S et al (2004) Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 64:665–671
Hemers E, Duval C, McCaig C et al (2005) Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymalsignaling. Cancer Res 65:7363–7369
Mochizuki S, Shimoda M, Shiomi T et al (2004) ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Bio Chem Biophys Res Commun 315:79–84
Sylvain MG, Thorsten M, Priya D et al (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123:3913–3922
Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176
Lahiry L, Saha B, Chakraborty J et al (2010) Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 31:259–268
Kessenbrock K, Wang WY, Werb Z (2015) Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol 44:184–190
Nasri I, Bonnet D, Zwarycz B et al (2016) PAR2-dependent activation of GSK3β regulates the survival of colon stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol 311:G221–G236
Amoury M, Kolberg K, Pham AT et al (2016) Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett 372:201–209
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292
Mohanty S, Saha S, Md D, Hossain S (2014) ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death Dis 5:e1021
Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5:275–284
Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
Eckford PD, Sharom FJ (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109:2989–3011
Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512
Wang J, Sullenger BA, Rich JN (2012) Notch signaling in cancer stem cells. Adv Exp Med Biol 727:174–185
Wang Z, Da Silva TG, Jin K et al (2014) Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res 74:6364–6374
D’Angelo RC, Ouzounova M, Davis A et al (2015) Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther 14:779–787
Theys J, Yahyanejad S, Habets R et al (2013) High Notch activity induces radiation resistance in non small cell lung cancer. Radiother Oncol1 08:440–445
Yahyanejad S, Theys J, Vooijs M (2016) Targeting Notch to overcome radiation resistance. Oncotarget 7:7610–7628
Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785
Lagadec C, Vlashi E, Alhiyari Y et al (2013) Radiation-induced Notch signaling in breast cancer stem cells. Int J Radiat Oncol Biol Phys 87:609–618
Mamaeva V, Niemi R, Beck M et al (2016) Inhibiting Notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ-secretase Inhibitors. Mol Ther 24:926–936
Austin KM, Covic L, Kuliopulos A (2013) Matrix metalloproteases and PAR1 activation. Blood 121:431–439
Fujimoto D, Ueda Y, Hirono Y et al (2015) PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway. Oncotarget 6:34788–34799
He YC, Zhou FL, Shen Y et al (2014) Apoptotic death of cancer stem cells for cancer therapy. Int J MolSci 15:8335–8351
Inohara N, Nuñez G (2001) The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 20:6473–6481
Cecconi F, Alvarez-Bolado G, Meyer BI et al (1998) Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94:727–737
Yoshida H, Kong YY, Yoshida R et al (1998) Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94:739–750
Yu CJ, Ou JH, Wang ML et al (2015) Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells. J BUON 20:1287–1294
Yan H, Tong J, Lin X et al (2015) Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells. Mol Med Rep 12:1783–1788
Jinesh GG, Choi W, Shah JB et al (2013) Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 20:382–395
Lu Y, Zhang C, Li Q et al (2015) Inhibitory effect of salinomycin on human breast cancer cells MDA-MB-231 proliferation through Hedgehog signaling pathway. Zhonghua Bing Li XueZaZhi 44:395–398
Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(436):444
Lowe DB, Storkus WJ (2011) Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy 3:1265–1274
Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081
Shigdar S, Li Y, Bhattacharya S et al (2014) Inflammation and cancer stem cells. Cancer Lett 345:271–278
Jinushi M (2014) Role of cancer stem cell-associated inflammation in creating pro-inflammatory tumorigenic microenvironments. Oncoimmunology 15:e28862
Hagemann T, Robinson SC, Schulz M et al (2004) Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25:1543–1549
Bengsch F, Buck A, Günther SC et al (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474–4484
Mohamed MM, Cavallo-Medved D, Rudy D et al (2010) Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 25:315–324
Gopinath S, Malla R, Alapati K et al (2013) Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression. Carcinogenesis 34:550–559
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148
Ryungsa K, Manabu E, Kazuaki T et al (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14
Swann Jeremy B, Smyth Mark J (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146
Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17:616–623
Waldhauer I, Steinle A (2008) NK cells and cancer immuno surveillance. Oncogene 27:5932–5943
Strik MC, de Koning PJ, Kleijmeer MJ et al (2007) Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. MolImmunol 44:3462–3472
Dimitriadou V, Koutsilieris M (1997) Mast cell–tumor cell interactions: for or against tumor growth and metastasis. Anticancer Res 17:1541–1549
Ames E, Canter RJ, Grossenbacher SK et al (2015) NK cells preferentially target tumor cells with a cancer stem cell phenotype. J Immunol 195:4010–4019
Waldhauer I, Goehlsdorf D, Gieseke F et al (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68:6368–6376
Jachetti E, Caputo S, Mazzoleni S et al (2015) Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation. Cancer Res 75:2095–2108
Sarkar S, Zemp FJ, Senger D et al (2015) ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells. Neuro Oncol 17:1095–1105
Remacle AG, Golubkov VS, Shiryaev SA, Dahl R, Stebbins JL, Chernov AV, Cheltsov AV, Pellecchia M, Strongin AY (2012) Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 72(9):2339–2349
Butler GS, Hutton M, Wattam BA et al (1999) The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J BiolChem 274:20391–20396
Djafarzadeh R, Noessner E, Engelmann H et al (2006) GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 25:1496–1508
Darini CY, Martin P, Azoulay S et al (2013) Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential. Cell Death Dis 4:e706
Bernstein WB, Dennis PA (2008) Repositioning HIV protease inhibitors as cancer therapeutics. CurrOpin HIV AIDS 3:666–675
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Khan, P., Banerjee, S., Bhattacharya, A., Chowdhury, D.D., Dutta, A., Das, T. (2017). Proteolytic Networks at the Crossroads of Cancer Cell Life and Death: Cancer Stem Cell Deciding Cell Fate. In: Chakraborti, S., Dhalla, N. (eds) Pathophysiological Aspects of Proteases. Springer, Singapore. https://doi.org/10.1007/978-981-10-6141-7_11
Download citation
DOI: https://doi.org/10.1007/978-981-10-6141-7_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6140-0
Online ISBN: 978-981-10-6141-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)